Were Analysts Bearish Mylan N.V. (NASDAQ:MYL) This Week?

September 16, 2018 - By Kyle Williams

Mylan N.V. (NASDAQ:MYL) LogoInvestors sentiment increased to 2 in 2018 Q2. Its up 1.00, from 1 in 2018Q1. It increased, as 2 investors sold Mylan N.V. shares while 0 reduced holdings. 3 funds opened positions while 1 raised stakes. 356,551 shares or 87.07% more from 190,596 shares in 2018Q1 were reported.
Gemmer Asset Management Ltd Liability reported 0% stake. Whittier Tru holds 0.37% of its portfolio in Mylan N.V. (NASDAQ:MYL) for 142,248 shares. 337 are owned by Vantage Investment Limited Com. Moreover, Gulf Intl Fincl Bank (Uk) has 0.08% invested in Mylan N.V. (NASDAQ:MYL) for 166,890 shares. Whittier Tru Communication Of Nevada holds 33,450 shares.

Mylan N.V. (NASDAQ:MYL) Ratings Coverage

Among 9 analysts covering Mylan Inc (NASDAQ:MYL), 7 have Buy rating, 0 Sell and 2 Hold. Therefore 78% are positive. Mylan Inc had 10 analyst reports since April 3, 2018 according to SRatingsIntel. The firm has “Outperform” rating given on Thursday, August 9 by Raymond James. The rating was maintained by Morgan Stanley on Monday, April 9 with “Buy”. The firm has “Outperform” rating given on Thursday, April 12 by Leerink Swann. The firm has “Buy” rating given on Thursday, April 12 by Mizuho. The company was maintained on Tuesday, May 29 by Bank of America. The firm has “Market Perform” rating given on Thursday, May 31 by Wells Fargo. The stock of Mylan N.V. (NASDAQ:MYL) earned “Outperform” rating by RBC Capital Markets on Monday, August 13. The company was maintained on Thursday, August 9 by Citigroup. The rating was maintained by Guggenheim on Tuesday, June 5 with “Buy”. RBC Capital Markets maintained Mylan N.V. (NASDAQ:MYL) on Tuesday, April 3 with “Hold” rating. Below is a list of Mylan N.V. (NASDAQ:MYL) latest ratings and price target changes.

13/08/2018 Broker: RBC Capital Markets Old Rating: Sector Perform New Rating: Outperform Old Target: $53 Upgrade
09/08/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $50 New Target: $48 Maintain
09/08/2018 Broker: Raymond James Old Rating: Strong Buy New Rating: Outperform Downgrade
05/06/2018 Broker: Guggenheim Rating: Buy New Target: $59.0000 Maintain
31/05/2018 Broker: Wells Fargo Old Rating: Market Perform New Rating: Market Perform Old Target: $43 New Target: $41 Maintain
29/05/2018 Broker: Bank of America Old Rating: Neutral New Rating: Neutral Old Target: $43 New Target: $42 Maintain
12/04/2018 Broker: Mizuho Rating: Buy New Target: $51.0000 Maintain
12/04/2018 Broker: Leerink Swann Old Rating: Market Perform New Rating: Outperform Old Target: $44 Upgrade
09/04/2018 Broker: Morgan Stanley Rating: Buy New Target: $50.0000 Maintain
03/04/2018 Broker: RBC Capital Markets Rating: Hold New Target: $45.0000 Maintain

The stock decreased 1.47% or $0.56 during the last trading session, reaching $37.48. About 2.43M shares traded. Mylan N.V. (NASDAQ:MYL) has risen 12.23% since September 16, 2017 and is uptrending. It has underperformed by 3.39% the S&P500.

Mylan N.V., together with its subsidiaries, develops, licenses, makes, markets, and distributes generic, brand name, and over-the-counter products worldwide. The company has market cap of $19.32 billion. The firm operates through three divisions: North America, Europe, and Rest of World. It has a 43.23 P/E ratio. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.

More important recent Mylan N.V. (NASDAQ:MYL) news were published by: Benzinga.com which released: “The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs” on September 16, 2018, also Streetinsider.com published article titled: “Theravance (TBPH), Mylan (MYL) to Report New Data from Phase 3 Studies of YUPELRI in Oral Presentation at ERS”, Seekingalpha.com published: “Mylan Grinding Towards Greatness” on September 04, 2018. More interesting news about Mylan N.V. (NASDAQ:MYL) was released by: Streetinsider.com and their article: “Mylan NV (MYL) Announces Launch of First Generic of Brevibloc Injection in Single-Dose Bags” with publication date: September 13, 2018.

Mylan N.V. (NASDAQ:MYL) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.